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Aspergillusfumigatusisanopportunistichumanpathogenicfungusresponsiblefordeadlylunginfectionsinimmunocompromised
individuals. Galactofuranose (Galf) residues are essential components of the cell wall and play an important role in A. fumigatus
virulence. The ﬂavoenzyme UDP-galactopyranose mutase (UGM) catalyzes the isomerization of UDP-galactopyranose to UDP-
galactofuranose, the biosynthetic precursor of Galf. Thus, inhibitors of UGM that block the biosynthesis of Galf c a nl e a dt on o v e l
chemotherapeutics for treating A. fumigatus-related diseases. Here, we describe the synthesis of ﬂuorescently labeled UDP analogs
and the development of a ﬂuorescence polarization (FP) binding assay for A. fumigatus UGM (AfUGM). High-aﬃnity binding to
AfUGM was only obtained with the chromophore TAMRA, linked to UDP by either 2 or 6 carbons with Kd values of 2.6±0.2μM
and 3.0 ± 0.7μM, respectively. These values were ∼6 times lower than when UDP was linked to ﬂuorescein. The FP assay was
validated against several known ligands and displayed an excellent Z
  factor (0.79±0.02) and good tolerance to dimethyl sulfoxide.
1.Introduction
Aspergillus fumigatus is an opportunistic human pathogen
responsible for diseases such as allergic reactions and
lung infections, including bronchopulmonary aspergillosis
(ABPA) and invasive pulmonary aspergillosis (IPA) [1, 2].
This fungus is a signiﬁcant health threat to immunocom-
promised patients, such as organ transplant recipients and
people with AIDS or leukemia [3, 4]. It has been reported
that IPA infections are typically accompanied by a mortality
rateof50–70%[5].Thus,identiﬁcationofnovelandeﬀective
drug targets is essential in the ﬁght against fungal infections.
Recently, the biosynthetic pathway of galactofuranose
(Galf), the 5-membered ring form of galactose, has been
describedinA.fumigatus.Galf isacomponentofthecellwall
of A. fumigatus and plays an important role in virulence [6–
8]. In A. fumigatus,G a l f was ﬁrst identiﬁed as a component
of galactomannan by immunodetection in IPA patients [9].
Later, it was found that Galf is also a major component
of saccharide structures in membrane lipids and glycosyl
phosphoinositol(GPI-)anchoredlipophospholipids[10,11].
UDP-galactopyranose mutase (UGM) is a ﬂavoenzyme that
catalyzes the conversion of UDP-galactopyranose (UDP-
Galp) to UDP-galactofuranose (UDP-Galf, Figure 1), the
biosynthetic precursor of Galf [7, 12]. Deletion of the A.
fumigatus UGM (AfUGM) gene results in mutant fungi
with attenuated virulence, a decrease in cell wall thickness,
and an increase in the sensitivity to antifungal agents
[8, 13]. Moreover, Galf is absent in humans [12]. Thus,
inhibitors of AfUGM that block the biosynthesis of Galf
represent attractive drug targets for the identiﬁcation of
novel therapeutics against A. fumigatus.
Here, we describe the development of a ﬂuorescence
polarization (FP) binding assay to identify speciﬁc AfUGM
inhibitors. Four ﬂuorescently labeled UDP derivatives
including two known UDP-ﬂuorescein analogs (1 and 2,
Figure 2) and two novel UDP-TAMRA analogs (3 and 4,
Figure 2) were synthesized to be used as ﬂuorescent probes
in the FP assay. Their concentrations were optimized to
obtain a stable FP signal with minimal standard deviation,
and their Kd values were determined by measuring the
anisotropy changes as a function of AfUGM concentration.2 Enzyme Research
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Figure 1: Reaction catalyzed by AfUGM.
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Figure 2: Synthetic scheme of the chromophores used as ligands to AfUGM for application in FP assays.
We found that the UDP-TAMRA analogs bind to AfUGM
6-fold tighter than the UDP-ﬂuorescein analogs, suggesting
that UDP-TAMRA analogs are better ﬂuorescent probes for
this enzyme. UDP-TAMRA probes could be competed out
by UDP, a known ligand of UGMs, and the Kd value of UDP
was in good agreement with the value determined previously
in a ﬂuorescence assay [7]. Furthermore, the FP assay was
validated using several known ligands and displayed an
excellent Z
  factor (0.79 ± 0.02) and good tolerance to
DMSO. Therefore, this fast convenient one-step FP assay is
suitable for a high-throughput screening to identify AfUGM
inhibitors.
2.MaterialsandMethods
2.1.Materials. Allchemicalswereobtainedfromcommercial
sources and were used without further puriﬁcation. Anhy-
drous reactions were performed under argon. All solvents
were either reagent grade or HPLC grade. NMR spectral
data were obtained using a JEOL Eclipse spectrometer at
500MHz, or a Varian Inova spectrometer at 400MHz.
Chemical shifts were reported as δ-values relative to known
solventresiduepeaks.High-resolutionmassspectra(HRMS)
were obtained in the Mass Spec Incubator, Department
of Biochemistry, Virginia Tech. High-performance liquid
chromatography (HPLC) was performed on a C18 reverse
phase column (Phenomenex Luna C18 column, 250 ×
21.20mm, 5 microns) using water and acetonitrile as the
elution solvents. All compounds were more than 95% pure
as judged by HPLC and 1H NMR.
2.2. Protein Expression and Puriﬁcation. AfUGM and
MtUGM were expressed and puriﬁed with the same pro-
t o c o la sd e s c r i b e db yO p p e n h e i m e re ta l .[ 7]. A large
quantity of highly pure AfUGM was obtained, which was
conﬁrmed by UV-visible spectrophotometry and SDS-PAGE
(see Figure S1 Supplementary Material available online at
doi:10.4061/2011/513905).
2.3. Synthesis of UDP-Fluorescein Chromophore 1 and 2. The
synthesis of chromophore 1 was accomplished by reactingEnzyme Research 3
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Figure 3: FP assay design. (a) Binding of the FP probe to AfUGM leads to polarized ﬂuorescence. (b) Displacement of the FP probe from
AfUGM by inhibitor results in depolarized ﬂuorescence.
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Figure 4: Determination of optimal concentration of ﬂuorescent
probe for FP binding assay. Conditions are described in Material
and Methods sections. Chromophore 1 ( ), 2 () (excitation at
492nm and emission at 524nm), 3 (), and 4 ()( e x c i t a t i o na t
544nm and emission at 584nm).
4mgofcompound5, which was synthesized following a pre-
viously published procedure [15], with 6mg of ﬂuorescein-
5-isothiocyanate (FITC) in 0.1M pH 9.0 NaHCO3 buﬀer
(50μL) and DMF (100μL) (Figure 2). After stirring at
room temperature for 2 hours, the yellow solution was
concentrated and loaded onto a preparative silica gel TLC
plate. The isolated crude product was dissolved in water,
injected onto reverse-phase HPLC (Phenomenex Luna C18
column, 250 × 21.20mm, 5 microns), and puriﬁed at a ﬂow
rate of 5.0mL/min with linear gradient elution of 5% to 95%
acetonitrile in H2Oo v e r2 0 m i nt oa ﬀord chromophore 1
(4mg,52%). 1HNMR(500MHz,6:1D2O:d7-DMF):δ 7.96
(d, J = 8.2, 1H), 7.78 (s, 1H), 7.70 (d, J = 8.1, 1H), 7.30 (dd, J
= 8.2, 1.5, 1H), 7.27-7.27 (m, 2H) (t, J = 8.7, 2H), 6.65–6.61
(m, 2H), 6.61–6.58 (m, 2H), 5.91 (s, 1H), 5.91 (s, 1H), 4.36–
4.30 (m, 2H), 4.24–4.21 (m, 3H), 4.19–4.16 (m, 2H), 3.88 (s,
2H); HRMS (MALDI) calcd for C32H29N4O17P2S (M-H)−:
835.0729, found 835.0759 (Figure S2).
Chromophore 2 (7.1mg, 55%) was synthesized from the
reaction of compound 6 and FITC by the same procedure
as above (Figure 2) and was puriﬁed by preparative TLC and
reverse-phase HPLC (Phenomenex Luna C18 column, 250
× 21.20mm, 5 micron). 1H NMR (500MHz, 6:1 D2O: d7-
DMF): δ 8.00 (d, J = 8.0, 1H), 7.73 (s, 1H), 7.61 (d, J = 8.3,
1H), 7.31 (d, J = 8.3, 1H), 7.27-7.27 (m, 2H), 6.66–6.60 (m,
4H), 5.96 (s, 1H), 4.38–4.34 (m, 2H), 4.27–4.23 (m, 2H),
4.23–4.18 (m, 2H), 3.97–3.92 (m, 2H), 3.58 (s, 1H), 1.66–
1.61 (m, 4H), 1.42–1.36 (m, 4H); HRMS (MALDI) calcd
for C36H37N4O17P2S (M-H)−: 891.1350, found 891.1348
(Figure S3).
2.4. Synthesis of UDP-TAMRA Chromophore 3 and 4. The
synthesis of chromophore 3 was accomplished by a reaction
of 4mg of compound 6, which was synthesized follow-
ing a previously published procedure [15], with 0.8mg
of 5-carboxytetramethylrhodamine, succinimidyl ester (5-
TAMRA, SE) in 0.1M pH 8.3 NaHCO3 buﬀer (50μL) and
DMF (50μL) (Figure 2). After stirring at room temperature
for 2 hours, the pink solution was concentrated and loaded
ontoapreparativeTLCplate.Theisolatedcrudeproductwas4 Enzyme Research
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Figure 5: FP binding assay to determine Kd of the chromophores. (a) Chromophores 1 ( )a n d2 () (excitation at 492nm and emission
at 524nm). (b) Chromophores 3 ()a n d4 ( ) (excitation at 544nm and emission at 584nm).
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Figure 6: Determination of optimal AfUGM concentration to use
in the FP assay with chromophore 3 () and chromophore 4 ( ).
dissolved in water, injected onto reverse-phase HPLC (Phe-
nomenex Luna C18 column, 250 × 21.20mm, 5 microns),
and puriﬁed at a ﬂow rate of 5.0mL/min with linear gradient
elution of 5% to 95% acetonitrile in H2Oo v e r2 0 m i nt o
aﬀord chromophore 3 (1.1mg, 80%). 1H NMR (500MHz,
D2O) δ 8.22 (s, 1H), 8.08 (d, J = 7.7, 1H), 7.89 (d, J = 7.3,
1H), 7.60 (d, J = 8.8, 1H), 7.28–7.22 (m, 1H), 6.91–6.88 (m,
2H), 6.61 (s, 1H), 6.59 (s, 1H), 5.89–5.83 (m, 2H), 4.35–
4.31 (m, 1H), 4.30–4.26 (m, 1H), 4.18–4.15 (m, 3H), 4.00
(dd, J = 13.3, 6.4, 2H), 3.49 (t, J = 6.8, 2H), 3.19 (s, 3H),
3.18 (s, 3H), 1.75 – 1.67 (m, 4H), 1.51–1.45 (m, 4H), 1.34 (s,
3H),1.32(s,3H);HRMS(MALDI)calcdforC40H46N5O16P2
(M-H)−: 914.2415, found 914.2431 (Figure S4). The above
synthetic approach was also used to synthesize and purify
chromophore 4 (1.5 mg, 77%). HRMS (MALDI) calcd for
C36H38N5O16P2 (M-H)−: 858.1789, found 858.1851 (Figure
S5).
2.5. Optimization of Chromophore Concentration. Solutions
containingvariousconcentrationsofchromophorein0.05M
sodium phosphate buﬀer (pH 7.0) were added to 12 wells
in a 96-well half area black bottom plate (Corning) with
ﬁnal volumes of 25μL. FP was analyzed by a SpectraMax M5
plate reader (Molecular Devices). The parallel ﬂuorescence
emission (F=) and perpendicular ﬂuorescence emission (F⊥)
at 524nm (for compounds 1 and 2, excitation at 492nm)
or at 584nm (for compounds 3 and 4, excitation at 544nm)
were measured by a SpectraMax M5 plate reader (Molecular
Devices), and the anisotropy (r) was calculated using (1),
the minimal concentration at which stable FP signals with
minimal standard deviations were chosen as the optimal
concentration for the chromophore.
r =
F= − G · F⊥
F= +2 G · F⊥
(1)
y = m1 +(m2 −m1)
×
(x +Ct +m3) −

(x +Ct +m3)
2 −4xCt
2Ct
(2)
2.6. FP Binding Assay to Determine the Chromophore Binding
Aﬃnities. Solutions containing serially diluted AfUGM and
15nM of chromophore in 0.05M sodium phosphate buﬀer
(pH 7.0) were incubated at room temperature for 5 minutes.Enzyme Research 5
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Figure 7: FP competitive binding assay with UDP (a) and UDP-Galp (b).
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Figure 8: Structures of known inhibitors of bacterial UGM [14].
Eachexperimentwasdoneintriplicateina96-wellblackbot-
tom plate at ﬁnal volumes of 25μL. Fluorescence anisotropy
was measured as indicated above, and the Kd values were
obtained by ﬁtting the anisotropy data to (2), where m1
and m2 are the minimum and maximum anisotropy values,
respectively; m3 is the Kd value, and the total concentration
of UDP-chromophore is represented by Ct.
2.7. Determination of the Assay Z  Factor. Solutions contain-
ing 2μMo fAfUGM and 15nM of chromophore 3 in the
absence (negative control) and presence (positive control) of
300μM of UDP were incubated at room temperature for 5
minutes. Each solution was added to octuplicate wells in a
96-well half area black bottom plate with ﬁnal volumes of
25μL. The Z
  factors were calculated using (3), where μ−
represents the mean anisotropy value of the negative control,
and μ+ is the mean anisotropy value of the positive control;
σ− represents the standard deviation of the negative control,
and σ+ is the standard deviation of the positive control. A Z
 
factor of 0.79 ± 0.02 was obtained for chromophore 3.
Z  = 1 −
3(σ− +σ+)
μ− − μ+
(3)
2.8. Optimization of AfUGM Concentration. To determine
the optimal concentration of AfUGM in the FP assay,
solutions containing 15nM of chromophore 3 and AfUGM
at various concentrations in the absence (negative control)
and presence (positive control) of 300μM of UDP were
incubated at room temperature for 5 minutes. Each was
added to octuplicate wells at a ﬁnal volume of 25μL. FP
was analyzed as indicated previously, and Z
  factors were
calculated from (3).
2.9. Competitive Binding Experiments Using FP Inhibition
Assay. Solutions (25μL) containing 2μMo fAfUGM and
15nM of chromophore 3 in 0.05M sodium phosphate buﬀer6 Enzyme Research
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Figure 9: FP inhibition assay with compounds 7 (a) and 8 (b).
(pH 7.0) were mixed with various concentrations of UDP,
UDP-Galp, 7,o r8 (Figure 8), and the reactions incubated
at room temperature for 5 minutes. Each solution was done
in triplicate. Anisotropy values were measured and the IC50
values obtained by ﬁtting the data to (4), where m1 and m2
aretheminimumandmaximumanisotropy,respectively;m3
is the slope, and m4 is the IC50.T h eKd values were obtained
using (5), where Ki is the binding aﬃnity of chromophore 3
on AfUGM (2.6 ± 0.6μM), and I is the concentration of the
chromophore (15nM).
y = m1 +
(m2 −m1)xm3
m
m3
4 +xm3 (4)
Kd =
IC50
1+(I/Ki)
(5)
2.10. AfUGM Activity Assay. The AfUGM activity assay was
performed by monitoring the formation of UDP-Galp from
UDP-Galf by HPLC. A 20μL reaction containing 20mM
dithiothreitol,0.5mMUDP-Galf in25mMHEPES,125mM
NaCl buﬀer, pH 7.5 in the absence of 7 or 8 was initiated
by the addition of AfUGM at a ﬁnal concentration of
50nM. After incubation at 37◦C for 10min, the reaction
was quenched by heat denaturation (95◦C for 5min) in a
DNA engine thermocycler (BioRad, Hercules, Calif, USA).
The same reaction was also performed in the presence
of 7 (500μM) or 8 (50μM). The suspension was cen-
trifuged and the supernatant was injected onto a CarboPac
PA100 (Dionex) anion-exchange column. The sample was
eluted isocratically with 75mM KH2PO4 (pH 4.5), and the
absorbance at 262nm was monitored to identify fractions of
substrateandproduct.ThesubstrateUDP-Galf waselutedat
36.5min, and the product UDP-Galp was eluted at 28.3min.
The inhibition of AfUGM activity was indicated by the
extent of conversion of UDP-Galf to UDP-Galp.
2.11. Tolerance to DMSO. To determine the tolerance of
the assay to DMSO, solutions containing 2μMo fAfUGM,
15nM of chromophore 3, and DMSO at various concen-
trations in the absence (negative control) and presence
(positive control) of 300μM of UDP were incubated at room
temperature for 5 minutes. Fluorescence anisotropy values
and Z
  factors were calculated as indicated previously.
3. Results and Discussion
3.1. Assay Design and Optimization. In this study, we report
the development of an FP assay that can be used in a high-
throughput format for the identiﬁcation of inhibitors of
AfUGM, which we believe will lead to the development
of new therapeutics against A. fumigatus-related diseases.
The FP assay was designed as shown in Figure 3. If the
UDP ﬂuorescent probe binds to AfUGM and is excited with
plane-polarized light, the resulting enzyme-ligand complex
tumbles slowly in solution, and thus, the ﬂuorescence
emission remains polarized (Figure 3(a)). Otherwise, the
emission will be depolarized as the free chromophore will
rotate rapidly. The change in the rotational motion between
the bound and free chromophore can be used as a signal
for detection of the binding of small molecules to the active
site of AfUGM because, as the small molecule replaces
the bound ﬂuorescent probe, the free probe will rapidly
rotate increasing the amount of depolarized ﬂuorescence
(Figure 3(b)).
An essential component of an FP assay is a ﬂuorescent
probe that speciﬁcally binds to the enzyme or protein of
interest. To design the ﬂuorescent probe, we reasoned that
the incorporation of the UDP moiety into the structure
would target binding to the AfUGM active site since it
is a major part of the UGM substrate. The ﬂuorophore
we ﬁrst selected was ﬂuorescein because UDP-ﬂuoresceinEnzyme Research 7
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Figure 10: AfUGM activity assay. The HPLC chromatograms at 262nm are shown. (a) AfUGM activity in the absence of inhibitor. (b) In
the presence of 7 (500μM). (c) In the presence of 8 (50μM).
derivatives have been found to bind to prokaryotic UGMs
from Klebsiella pneumoniae and Mycobacterium tuberculosis
[15]. To minimize the steric hindrance of ﬂuorescein with
AfUGM binding site residues, UDP and ﬂuorescein were
connected with alkyl linkers of diﬀerent lengths, which
resulted in two UDP-ﬂuorescein analogs (1 and 2, Figure 2).
We also designed a UDP bound to the chromophore, com-
mercially known as TAMRA (Figure 2). This chromophore
oﬀers several advantages over ﬂuorescein. First, TAMRA is
more resistant to photobleaching compared to ﬂuorescein
[16]. Second, the ﬂuorescence emission of TAMRA does
not overlap with that of the ﬂavin cofactor in AfUGM.
Fluorescein is typically excited at 494nm and emits at
520nm, which signiﬁcantly overlaps with the absorbance
andﬂuorescenceemissionoftheﬂavin.Incontrast,TAMRA’s
absorbance and ﬂuorescence maxima is at 546 nm and 580
nm, respectively [16]. This is signiﬁcantly diﬀerent from
the ﬂavin absorbance/emission properties and improves
signal-to-noiseratio.Finally,incomparisonwithﬂuorescein,
TAMRA has one extra positive charge, which we believe
increases the interaction between TAMRA and ﬂavin and
helps improve binding of the probe to AfUGM. Alkyl linkers
of diﬀerent lengths were also included to minimize the steric
interaction of TAMRA with the binding site residues, giving
two novel UDP-TAMRA analogs (3 and 4, Figure 2).
In order to increase the signal-to-noise ratio, stable FP
values are necessary. Therefore, we varied the concentration
of UDP-chromophores to determine the optimal concentra-
tion(Figure 4).StableFPvalueswithminimalstandarddevi-
ation were obtained at concentrations higher than 15nM.
Therefore, we chose the 15nM UDP-chromophore as the
minimal concentration to use for further characterization.
3.2. AfUGM Speciﬁc UDP-Chromophore for HTS Assay Appli-
cation. Binding of the UDP-chromophore to AfUGM was8 Enzyme Research
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Figure 11: Tolerance to DMSO.
Table 1: Kd values of UDP-ﬂuorescent probes.
Chromophore Kd for AfUGM (μM) Kd for MtUGM (μM)
1 17 ± 3 >30
2 16 ± 30 . 1 0 ± 0.01
3 2.6 ± 0.2 0.73 ± 0.07
4 3.0 ± 0.7 >30
determined by varying the concentration of the enzyme at a
constant concentration of the UDP-chromophores (15nM)
(Figure 5). Binding assays with the UDP-ﬂuorescein probes
(chromophores 1 and 2) show that these ligands bind
weakly to AfUGM, with Kd values of ∼15μM( Figure 5(a)).
This relatively low aﬃnity impedes the utilization of these
chromophores for a high-throughput FP binding assay, as
it will require high quantities of enzyme. Interestingly, we
tested the binding of these chromophores to bacterial UGM
from M. tuberculosis, and the Kd value of chromophore 2 was
0.10 ± 0.01μM, consistent with previously published values
(Table 1)[ 15]. This tighter binding suggests diﬀerences in
the active-site architecture between the prokaryotic and
A. fumigatus UGM enzymes. This is also consistent with
our recent report on binding assays monitoring ﬂavin
ﬂuorescence that showed that AfUGM binds UDP-glucose
5 times tighter than K. pneumoniae UGM. Similarly, binding
of UDP-Galp to AfUGM was not detected although UDP-
Galp binds to the bacterial enzyme with a Kd value of
220μM[ 7, 17]. These diﬀerences in ligand binding might
originate from the low amino acid identity between the
bacterial and eukaryotic UGMs (<18%). Furthermore, we
have shown that the quaternary structure between these
enzymes is not conserved as the bacterial enzymes have been
shown to function as homodimers, while AfUGM functions
as a homotetramer [7].
WiththeUDP-TAMRAanalogs(chromophores3and4),
the binding to AfUGM was ∼6 times better than with the
UDP-ﬂuorescein analogs, and signiﬁcant anisotropy change
Table 2: Kd values of UGM ligands.
Ligand Kd for AfUGM (μM) Kd for MtUGM (μM)
UDP 9.0 ± 1.7 15 ± 2
UDP-Galp 495 ± 66 563 ± 75
7 140 ± 92 1 ± 1
8 11 ± 0.4 25 ± 2
was measured (Figure 5(b)). Interestingly, the length of
the linker had little or no eﬀect on the binding aﬃnities
(Table 1), suggesting that with AfUGM the interaction
between the chromophore and some components of the
active site or perhaps directly with the ﬂavin cofactor play a
majorroleinbinding.Compound3and4boundtoMtUGM
with similar aﬃnities as chromophores 1 and 2,r e s p e c t i v e l y .
In contrast to AfUGM, in the bacterial enzymes, the length
of the linker plays a major role in binding with longer
linkers increasing the aﬃnity, further demonstrating that the
active-site architecture varied among the UGM enzymes. We
selected 3 as the FP probe for further characterization of the
binding assay.
3.3. Determination of Competitive Binding Using FP Assay.
FP competitive inhibition binding assay was conducted to
conﬁrmthattheFPprobesbindtotheactivesiteonAfUGM.
First, the Z
  factor as a function of AfUGM was determined
to establish the proper enzyme concentration to be used in
the assay. The Z
  factor is a statistical parameter that reports
on the quality of the assay [18]. As shown in Figure 6, the FP
assay exhibits excellent quality at an AfUGM concentration
higher than 2μMw i t haZ
  factor above 0.8. The minimum
value (2μM) in this range was selected as the optimal assay
concentration.
The Kd for UDP was determined using the FP assay by
titrating AfUGM with serial dilutions of UDP. A value of
9.0 ± 1.7μM was obtained, which is in good agreement
with the Kd (33 ± 9μM) previously determined by directly
monitoring the ﬂavin ﬂuorescence (Figure 7(a))[ 7].
UDP-Galp was the second ligand tested in the FP
inhibition assay, and a Kd value of 495 ± 66μMw a s
calculated (Figure 7(b)), indicating that UDP-Galp is a poor
ligand for AfUGM, which agrees well with the observation
previously reported by Oppenheimer et al. [7].
Recently, a series of prokaryotic UGM inhibitors were
identiﬁed from chemical libraries by high-throughput
screening (HTS) [14]. In our FP assay, we tested two of
the best prokaryotic UGM inhibitors, compound 7 and
compound 8 (Figure 8). Interestingly, they behaved diﬀer-
ently on AfUGM. Compound 7 turned out to be a poor
ligand for AfUGM with a Kd of 140 ± 9μM( Figure 9(a)).
In contrast, compound 8 exhibits much better binding to
AfUGM (Figure 9(b)), and its Kd was found to be 11
± 0.4μM( Table 2). We also tested these two compounds
in a secondary assay, directly monitoring the activity of
AfUGM to see if these molecules function as inhibitors. The
HPLC chromatograms (Figure 10) indicated that both of the
compounds inhibit the activity of AfUGM. These resultsEnzyme Research 9
conﬁrm that the FP assay identiﬁes ligands that bind to the
active site of AfUGM and that these molecules inhibit the
activity of the enzyme in a secondary assay that directly
measures product formation.
3.4. FP Assay Quality. The Z
  factor value using chro-
mophore 3 was calculated to be 0.79 ± 0.02. An assay with
aZ
  factor greater than 0.5 is considered a good assay;
therefore, our FP assay is suitable for HTS (Figure 6). We
also estimated the tolerance of the FP assay to DMSO by
calculating the Z
  factors at various DMSO concentrations,
because a majority of compounds in HTS libraries are
dissolved in DMSO. The Z
  factors were plotted against
DMSOconcentrationstogenerateaDMSOcalibrationcurve
(Figure 11), and our assay maintains excellent quality with
DMSO concentration up to 5% (v/v).
4. Conclusion
In conclusion, four ﬂuorescently labeled UDP derivatives
(1–4) were synthesized and tested for binding to AfUGM.
Diﬀerent from the bacterial UGM, the nature of the chro-
mophore enhanced binding to AfUGM while the length of
the linkers did not. UDP-TAMRA analogs (3 and 4) bind to
AfUGM with high aﬃnities. Binding of chromophore 3 to
the active site of AfUGM was demonstrated by a competi-
tion experiment using UDP and UDP-Galp. Furthermore,
binding of known inhibitors of bacterial UGM was tested
against AfUGM, and it was found that these compounds
bound AfUGM, however, with lower aﬃnities. Inhibition
of AfUGM, measuring product formation by HPLC, was
demonstrated with compounds 7 and 8.AZ
  factor of 0.79
was calculated, and the assay was shown to exhibit good
tolerance to DMSO. We expect that the FP assay described
here will allow fast identiﬁcation of AfUGM inhibitors from
chemical libraries. We believe that inhibitors of AfUGM
that block the biosynthesis of Galf could lead to novel
therapeutics against A. fumigatus-related diseases.
Acknowledgments
This work was supported in part by NIH Grants RO1
GM094469 (P. Sobrado, PI) and RO1 AI082542 (R. Tarleton,
PI). M. Oppenheimer was supported by a fellowship from
the American Heart Association.
References
[ 1 ]R .J .T r o f ,A .B e i s h u i z e n ,Y .J .D e b e t s - O s s e n k o p p ,A .R .
J. Girbes, and A. B. J. Groeneveld, “Management of inva-
sive pulmonary aspergillosis in non-neutropenic critically ill
patients,” Intensive Care Medicine, vol. 33, no. 10, pp. 1694–
1703, 2007.
[2] R. L. Kradin and E. J. Mark, “The pathology of pulmonary
disorders due to Aspergillus spp,” Archives of Pathology and
Laboratory Medicine, vol. 132, no. 4, pp. 606–614, 2008.
[ 3 ]S .C h o n g ,T .S .K i m ,W .J .K o h ,E .Y .C h o ,a n dK .K i m ,
“Invasive pulmonary aspergillosis complicated by pulmonary
artery occlusion in an immunocompetent patient,” Clinical
Radiology, vol. 61, no. 3, pp. 287–290, 2006.
[4] C. Virnig and R. K. Bush, “Allergic bronchopulmonary
aspergillosis: a US perspective,” Current Opinion in Pulmonary
Medicine, vol. 13, no. 1, pp. 67–71, 2007.
[ 5 ]G .C h a m i l o s ,M .L u n a ,R .E .L e w i se ta l . ,“ I n v a s i v ef u n g a l
infections in patients with hematologic malignancies in a
tertiary care cancer center: an autopsy study over a 15-year
period (1989–2003),” Haematologica, vol. 91, no. 7, pp. 986–
989, 2006.
[6] J. P. Latge, “Galactofuranose containing molecules in
Aspergillus fumigatus,” Medical Mycology, vol. 47, 1, pp.
S104–S109, 2009.
[7] M. Oppenheimer, M. B. Poulin, T. L. Lowary, R. F. Helm,
a n dP .S o b r a d o ,“ C h a r a c t e r i z a t i o no fr e c o m b i n a n tU D P -
galactopyranose mutase from Aspergillus fumigatus,” Archives
ofBiochemistryandBiophysics,vol.502,no.1,pp.31–38,2010.
[8] P.S.Schmalhorst,S.Krappmann,W.Verveckenetal.,“Contri-
butionofgalactofuranosetothevirulenceoftheopportunistic
pathogen Aspergillus fumigatus,” Eukaryotic Cell, vol. 7, no. 8,
pp. 1268–1277, 2008.
[9] D. Stynen, A. Goris, J. Sarfati, and J. P. Latge, “A new
sensitive sandwich enzyme-linked immunosorbent assay to
detect galactofuran in patients with invasive Aspergillosis,”
Journal of Clinical Microbiology, vol. 33, no. 2, pp. 497–500,
1995.
[10] C. Costachel, B. Coddeville, J. P. Latg´ e, and T. Fontaine,
“Glycosylphosphatidylinositol-anchored fungal polysaccha-
ride in Aspergillus fumigatus,” Journal of Biological Chemistry,
vol. 280, no. 48, pp. 39835–39842, 2005.
[11] C. Simenel, B. Coddeville, M. Delepierre, J. P. Latg´ e, and
T.Fontaine,“GlycosylinositolphosphoceramidesinAspergillus
fumigatus,” Glycobiology, vol. 18, no. 1, pp. 84–96, 2008.
[12] P. M. Nassau, S. L. Martin, R. E. Brown et al., “Galactofu-
ranose biosynthesis in Escherichia coli K-12: identiﬁcation
and cloning of UDP-galactopyranose mutase,” Journal of
Bacteriology, vol. 178, no. 4, pp. 1047–1052, 1996.
[13] J. Engel, P. S. Schmalhorst, T. D¨ ork-Bousset, V. Ferri` eres, and
F. H. Routier, “A single UDP-galactofuranose transporter is
required for galactofuranosylation in Aspergillus fumigatus,”
Journal of Biological Chemistry, vol. 284, no. 49, pp. 33859–
33868, 2009.
[14] E. E. Carlson, J. F. May, and L. L. Kiessling, “Chemical Probes
of UDP-Galactopyranose Mutase,” Chemistry and Biology, vol.
13, no. 8, pp. 825–837, 2006.
[15] E. C. Dykhuizen and L. L. Kiessling, “Potent ligands for
prokaryotic UDP-galactopyranose mutase that exploit an
enzyme subsite,” Organic Letters, vol. 11, no. 1, pp. 193–196,
2009.
[16] R. P. Haugland, Handbook of Fluorescent Probes and Research
Chemicals, Molecular Probes, Eugene, Ore, USA, 1996.
[17] X. Yao, D. W. Bleile, Y. Yuan et al., “Substrate directs enzyme
dynamics by bridging distal sites: UDP-galactopyranose
mutase,” Proteins, vol. 74, no. 4, pp. 972–979, 2009.
[18] J. H. Zhang, T. D. Y. Chung, and K. R. Oldenburg, “A simple
statistical parameter for use in evaluation and validation of
high throughput screening assays,” Journal of Biomolecular
Screening, vol. 4, no. 2, pp. 67–73, 1999.